VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

Adjuvant imatinib is indicated after complete resection of primary localized GIST at high risk of recurrence. Many of these patients relapse after the end of 3 year adjuvant imatinib. Whether prolonging adjuvant imatinib beyond 3 years may reduce GIST recurrence has not been explored in a randomized setting.